The lncRNA Plscr4 Controls Cardiac Hypertrophy by Regulating miR-214
Cardiac hypertrophy accompanied by maladaptive cardiac remodeling is the uppermost risk factor for the development of heart failure. Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have various biological functions, and their vital role in the regulation of cardiac hypertrophy still needs to b...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2018-03-01
|
| Series: | Molecular Therapy: Nucleic Acids |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253117303190 |
| _version_ | 1811221664084525056 |
|---|---|
| author | Lifang Lv Tianyu Li Xuelian Li Chaoqian Xu Qiushuang Liu Hua Jiang Yingnan Li Yingqi Liu He Yan Qihe Huang Yuhong Zhou Mingyu Zhang Hongli Shan Haihai Liang |
| author_facet | Lifang Lv Tianyu Li Xuelian Li Chaoqian Xu Qiushuang Liu Hua Jiang Yingnan Li Yingqi Liu He Yan Qihe Huang Yuhong Zhou Mingyu Zhang Hongli Shan Haihai Liang |
| author_sort | Lifang Lv |
| collection | DOAJ |
| description | Cardiac hypertrophy accompanied by maladaptive cardiac remodeling is the uppermost risk factor for the development of heart failure. Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have various biological functions, and their vital role in the regulation of cardiac hypertrophy still needs to be explored. In this study, we demonstrated that lncRNA Plscr4 was upregulated in hypertrophic mice hearts and in angiotensin II (Ang II)–treated cardiomyocytes. Next, we observed that overexpression of Plscr4 attenuated Ang II-induced cardiomyocyte hypertrophy. Conversely, the inhibition of Plscr4 gave rise to cardiomyocyte hypertrophy. Furthermore, overexpression of Plscr4 attenuated TAC (transverse aortic constriction)-induced cardiac hypertrophy. Finally, we demonstrated that Plscr4 acted as an endogenous sponge of miR-214 and forced expression of Plscr4 downregulated miR-214 expression to promote Mfn2 and attenuate hypertrophy. In contrast, knockdown of Plscr4 upregulated miR-214 to induce cardiomyocyte hypertrophy. Additionally, luciferase assay showed that miR-214 was the direct target of Plscr4, and overexpression of miR-214 counteracted the anti-hypertrophy effect of Plscr4. Collectively, these findings identify Plscr4 as a negative regulator of cardiac hypertrophy in vivo and in vitro due to its regulation of the miR-214-Mfn2 axis, suggesting that Plscr4 might act as a therapeutic target for the treatment of cardiac hypertrophy and heart failure. |
| first_indexed | 2024-04-12T08:03:32Z |
| format | Article |
| id | doaj.art-742eaa48c3a94deeb48e4a619f02b4d3 |
| institution | Directory Open Access Journal |
| issn | 2162-2531 |
| language | English |
| last_indexed | 2024-04-12T08:03:32Z |
| publishDate | 2018-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular Therapy: Nucleic Acids |
| spelling | doaj.art-742eaa48c3a94deeb48e4a619f02b4d32022-12-22T03:41:14ZengElsevierMolecular Therapy: Nucleic Acids2162-25312018-03-011038739710.1016/j.omtn.2017.12.018The lncRNA Plscr4 Controls Cardiac Hypertrophy by Regulating miR-214Lifang Lv0Tianyu Li1Xuelian Li2Chaoqian Xu3Qiushuang Liu4Hua Jiang5Yingnan Li6Yingqi Liu7He Yan8Qihe Huang9Yuhong Zhou10Mingyu Zhang11Hongli Shan12Haihai Liang13Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150081, ChinaDepartment of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150081, ChinaDepartment of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150081, ChinaDepartment of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150081, ChinaDepartment of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150081, ChinaDepartment of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150081, China; Northern Translational Medicine Research and Cooperation Center, Heilongjiang Academy of Medical Sciences, Harbin Medical University, Harbin, Heilongjiang 150081, ChinaDepartment of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150081, ChinaDepartment of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150081, ChinaDepartment of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150081, China; Northern Translational Medicine Research and Cooperation Center, Heilongjiang Academy of Medical Sciences, Harbin Medical University, Harbin, Heilongjiang 150081, ChinaDepartment of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150081, ChinaDepartment of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150081, ChinaDepartment of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150081, ChinaDepartment of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150081, China; Northern Translational Medicine Research and Cooperation Center, Heilongjiang Academy of Medical Sciences, Harbin Medical University, Harbin, Heilongjiang 150081, China; Corresponding author: Professor Hongli Shan, Baojian Road 157, Harbin, Heilongjiang 150081, China.Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150081, China; Northern Translational Medicine Research and Cooperation Center, Heilongjiang Academy of Medical Sciences, Harbin Medical University, Harbin, Heilongjiang 150081, China; Corresponding author: Professor Haihai Liang, Baojian Road 157, Harbin, Heilongjiang 150081, China.Cardiac hypertrophy accompanied by maladaptive cardiac remodeling is the uppermost risk factor for the development of heart failure. Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have various biological functions, and their vital role in the regulation of cardiac hypertrophy still needs to be explored. In this study, we demonstrated that lncRNA Plscr4 was upregulated in hypertrophic mice hearts and in angiotensin II (Ang II)–treated cardiomyocytes. Next, we observed that overexpression of Plscr4 attenuated Ang II-induced cardiomyocyte hypertrophy. Conversely, the inhibition of Plscr4 gave rise to cardiomyocyte hypertrophy. Furthermore, overexpression of Plscr4 attenuated TAC (transverse aortic constriction)-induced cardiac hypertrophy. Finally, we demonstrated that Plscr4 acted as an endogenous sponge of miR-214 and forced expression of Plscr4 downregulated miR-214 expression to promote Mfn2 and attenuate hypertrophy. In contrast, knockdown of Plscr4 upregulated miR-214 to induce cardiomyocyte hypertrophy. Additionally, luciferase assay showed that miR-214 was the direct target of Plscr4, and overexpression of miR-214 counteracted the anti-hypertrophy effect of Plscr4. Collectively, these findings identify Plscr4 as a negative regulator of cardiac hypertrophy in vivo and in vitro due to its regulation of the miR-214-Mfn2 axis, suggesting that Plscr4 might act as a therapeutic target for the treatment of cardiac hypertrophy and heart failure.http://www.sciencedirect.com/science/article/pii/S2162253117303190cardiac hypertrophylncRNA Plscr4miR-214Mfn2 |
| spellingShingle | Lifang Lv Tianyu Li Xuelian Li Chaoqian Xu Qiushuang Liu Hua Jiang Yingnan Li Yingqi Liu He Yan Qihe Huang Yuhong Zhou Mingyu Zhang Hongli Shan Haihai Liang The lncRNA Plscr4 Controls Cardiac Hypertrophy by Regulating miR-214 Molecular Therapy: Nucleic Acids cardiac hypertrophy lncRNA Plscr4 miR-214 Mfn2 |
| title | The lncRNA Plscr4 Controls Cardiac Hypertrophy by Regulating miR-214 |
| title_full | The lncRNA Plscr4 Controls Cardiac Hypertrophy by Regulating miR-214 |
| title_fullStr | The lncRNA Plscr4 Controls Cardiac Hypertrophy by Regulating miR-214 |
| title_full_unstemmed | The lncRNA Plscr4 Controls Cardiac Hypertrophy by Regulating miR-214 |
| title_short | The lncRNA Plscr4 Controls Cardiac Hypertrophy by Regulating miR-214 |
| title_sort | lncrna plscr4 controls cardiac hypertrophy by regulating mir 214 |
| topic | cardiac hypertrophy lncRNA Plscr4 miR-214 Mfn2 |
| url | http://www.sciencedirect.com/science/article/pii/S2162253117303190 |
| work_keys_str_mv | AT lifanglv thelncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT tianyuli thelncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT xuelianli thelncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT chaoqianxu thelncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT qiushuangliu thelncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT huajiang thelncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT yingnanli thelncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT yingqiliu thelncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT heyan thelncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT qihehuang thelncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT yuhongzhou thelncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT mingyuzhang thelncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT honglishan thelncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT haihailiang thelncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT lifanglv lncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT tianyuli lncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT xuelianli lncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT chaoqianxu lncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT qiushuangliu lncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT huajiang lncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT yingnanli lncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT yingqiliu lncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT heyan lncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT qihehuang lncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT yuhongzhou lncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT mingyuzhang lncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT honglishan lncrnaplscr4controlscardiachypertrophybyregulatingmir214 AT haihailiang lncrnaplscr4controlscardiachypertrophybyregulatingmir214 |